| Identification | Back Directory | [Name]
Fosravuconazole | [CAS]
351227-64-0 | [Synonyms]
E-1224)
BMS-379224
Fosravuconazole
SYTNEMZCCLUTNX-NPMXOYFQSA-N
Fosravuconazole (Synonyms: BMS-379224
Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-1-methyl-2-[(phosphonooxy)methoxy]-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]- | [Molecular Formula]
C23H20F2N5O5PS | [MDL Number]
MFCD28963981 | [MOL File]
351227-64-0.mol | [Molecular Weight]
547.47 |
| Chemical Properties | Back Directory | [Boiling point ]
783.7±70.0 °C(Predicted) | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
1?+-.0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Fosravuconazole (BMS-379224), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole can be used for candidiasis, onychomycosis and parasitemia research[1][2][3]. | [Definition]
ChEBI: BMS 379224 is an amine. | [in vivo]
Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[3]. | Animal Model: | Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain)[3]. | | Dosage: | 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg | | Administration: | Oral administration; daily; for 20 days | | Result: | Suppressed the parasitemia and prevented death. |
| [storage]
Store at -20°C | [References]
[1] Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159. DOI:10.1111/1346-8138.14607
[2] Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278. DOI:10.1016/j.parint.2020.102278
[3] Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18. DOI:10.1128/AAC.00401-18 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|